Correction: Simvastatin attenuates the development of pulmonary and cutaneous fibrosis in a murine model of systemic sclerosis (Rheumatology (2013) 52:8 (1377-1386) DOI: 10.1093/rheumatology/ket144);Simvastatin attenuates the development of pulmonary and cutaneous fibrosis in a murine model of systemic sclerosis

Rheumatology (United Kingdom)

Volumn 52, Issue 8, 2013, Pages 1377-1386

  Bagnato, Gianluca ^a   Bitto, Alessandra ^a   Pizzino, Gabriele ^a   Irrera, Natasha ^a   Sangari, Donatella ^b   Cinquegrani, Maurizio ^a   Roberts, William Neal ^c   Cerinic, Marco Matucci ^d   Squadrito, Francesco ^a   Altavilla, Domenica ^a   Bagnato, Gianfilippo ^b   Saitta, Antonino ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c University of Louisville School of Medicine   (United States)

^d UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Animal model; Pulmonary fibrosis; Reactive oxygen species; Simvastatin; Systemic sclerosis

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANTIFIBROTIC AGENT; MITOGEN ACTIVATED PROTEIN KINASE; RAS PROTEIN; RHO FACTOR; SIMVASTATIN; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG FIBROSIS; MOUSE; MYOFIBROBLAST; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SKIN BIOPSY; SKIN FIBROSIS; SKINFOLD THICKNESS; SYSTEMIC SCLEROSIS; WESTERN BLOTTING;

EID: 84880624539     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kead255     Document Type: Erratum

References (49)

1. Wei J, Bhattacharyya S, Tourtellotte WG et al. Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy. Autoimmun Rev 2011;10:267-75.
2. Ramos-Casals M, Fonollosa-Pla V, Brito-Zerón P et al. Targeted therapy for systemic sclerosis: how close are we? Nat Rev Rheumatol 2010;6:269-78.
3. Ong VH, Denton CP. Innovative therapies for systemic sclerosis. Curr Opin Rheumatol 2010;22: 264-72.
4. Aktunc E, Kayhan B, Arasli M et al. The effect of atorvastatin and its role on systemic cytokine network in treatment of acute experimental colitis. Immunopharmacol Immunotoxicol 2011;33:667-75.
5. Eller P, Eller K, Wolf AM et al. Atorvastatin attenuates murine anti-glomerular basement membrane glomerulonephritis. Kidney Int 2010;77:428-35.
6. Sato K, Nuki T, Gomita K et al. Statins reduce endothelial cell apoptosis via inhibition of TRAIL expression on activated CD4 T cells in acute coronary syndrome. Atherosclerosis 2010;213:33-9.
7. Clockaerts S, Van Osch GJ, Bastiaansen-Jenniskens YM et al. Statin use is associated with reduced incidence and progression of knee osteoarthritis in the Rotterdam study. Ann Rheum Dis 2012;71:642-7.
8. Zeki AA, Thai P, Kenyon NJ et al. Differential effects of simvastatin on IL-13-induced cytokine gene expression in primary mouse tracheal epithelial cells. Respir Res 2012; 13:38.
9. Davis BB, Zeki AA, Bratt JM et al. Simvastatin inhibits smoke-induced airway epithelial injury: implications for COPD therapy. Eur Respir J 2012, Nov 22 [Epub ahead of print].
10. Soma MR, Corsini A, Paoletti R. Cholesterol and mevalonic acid modulation in cell metabolism and multiplication. Toxicol Lett 1992;64-5:1-15.
11. Kauffmann-Zeh A, Rodriguez-Viciana P, Ulrich E et al. Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature 1997;385:544-8.
12. Marshall CJ. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signalregulated kinase activation. Cell 1995;80:179-85.
13. Tan A, Levrey H, Dahm C et al. Lovastatin induces fibroblast apoptosis in vitro and in vivo. A possible therapy for fibroproliferative disorders. Am J Respir Crit Care Med 1999;159:220-7.
14. Servettaz A, Goulvestre C, Kavian N et al. Selective oxidation of DNA topoisomerase 1 induces systemic sclerosis in the mouse. J Immunol 2009;182:5855-64.
15. Mundy GR, Garrett S, Harris J et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999; 286:1946-9.
16. Ni W, Egashira C, Kataoka C et al. Antiinflammatory and antiarteriosclerotic actions of HMGCoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis. Circ Res 2001;89:415-21.
17. Li YJ, Azuma A, Usuki J et al. EM703 improves bleomycininduced pulmonary fibrosis in mice by the inhibition of TGF-b signalling in lung fibroblasts. Respir Res 2006;7:16.
18. De Langhe E, Vande Velde G, Hostens J et al. Quantification of lung fibrosis and emphysema in mice using automated micro-computed tomography. PLoS One 2012;7:e43123.
19. Akhmetshina A, Dees C, Pileckyte M et al. Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J 2008;22:2214-22.
20. Skhirtladze C, Distler O, Dees C et al. Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis. Arthritis Rheum 2008;58:1475-84.
21. Ashcroft T, Simpson JM, Timbrell V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol 1988;41:467-70.
22. Carlin CM, Celnick DF, Pak O et al. Low dose fluvastatin reverses the hypoxic pulmonary adventitial fibroblast phenotype in experimental pulmonary hypertension. Am J Respir Cell Mol Biol 2012;47:140-8.
23. Carlin CM, Peacock AJ, Welsh DJ. Fluvastatin inhibits hypoxic proliferation and p38 MAPK activity in pulmonary artery fibroblasts. Am J Respir Cell Mol Biol 2007;37: 447-56.
24. Del Papa N, Cortiana M, Vitali C et al. Simvastatin reduces endothelial activation and damage but is partially ineffective in inducing endothelial repair in systemic sclerosis. J Rheumatol 2008;35:1323-8.
25. Kuwana M, Kaburaki J, Okazaki Y et al. Increase in circulating endothelial precursors by atorvastatin in patients with systemic sclerosis. Arthritis Rheum 2006;54:1946-51.
26. Kuwana M, Okazaki Y, Kaburaki J. Long-term beneficial effects of statins on vascular manifestations in patients with systemicsclerosis. Mod Rheumatol 2009;19: 530-5.
27. Abou-Raya A, Abou-Raya S, Helmii M. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers. J Rheumatol 2008;35: 1801-8.
28. Zhang FL, Casey PJ. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 1999;65:241-69.
29. Liao JK. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 2005;96:24F-33F.
30. Goppelt-Struebe M, Hahn A, Iwanciw D et al. Regulation of connective tissue growth factor (ccn2; ctgf) gene expression in human mesangial cells: modulation by HMG CoA reductase inhibitors (statins). Mol Pathol 2001;54:176-9.
31. Eberlein M, Heusinger-Ribeiro J, Goppelt-Struebe M. Rho-dependent inhibition of the induction of connective tissue growth factor (CTGF) by HMG CoA reductase inhibitors (statins). Br J Pharmacol 2001;133:1172-80.
32. Copaja M, Venegas D, Aránguiz P et al. Simvastatin induces apoptosis by a Rho-dependent mechanism in cultured cardiac fibroblasts and myofibroblasts. Toxicol Appl Pharmacol 2011;255:57-64.
33. Louneva N, Huaman G, Fertala J et al. Inhibition of systemic sclerosis dermal fibroblast type I collagen production and gene expression by simvastatin. Arthritis Rheum 2006;54:1298-308.
34. Ou XM, Feng YL, Wen FQ et al. Simvastatin attenuates bleomycin-induced pulmonary fibrosis in mice. Chin Med J (Engl) 2008;121:1821-9.
35. Ding WY, Ti Y, Wang J et al. Prostaglandin F2a facilitates collagen synthesis in cardiac fibroblasts via an F-prostanoid receptor/protein kinase C/Rho kinase pathway independent of transforming growth factor b1. Int J Biochem Cell Biol 2012;44:1031-9.
36. Cantin AM, North SL, Fells GA et al. Oxidant-mediated epithelial cell injury in idiopathic pulmonary fibrosis. J Clin Invest 1987;79:1665-73.
37. Kondrikov D, Caldwell RB, Dong Z et al. Reactive oxygen species-dependent RhoA activation mediates collagen synthesis in hyperoxic lung fibrosis. Free Radic Biol Med 2011;50:1689-98.
38. Jiang C, Huang H, Liu J et al. Fasudil, a rho-kinase inhibitor, attenuates bleomycin-induced pulmonary fibrosis in mice. Int J Mol Sci 2012;13:8293-307.
39. Patel S, Mason RM, Suzuki J et al. Inhibitory effect of statins on renal epithelial-to-mesenchymal transition. Am J Nephrol 2006;26:381-7.
40. Kim KK, Kugler MC, Wolters PJ et al. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary Ebrosis and is regulated by the extracellular matrix. Proc Natl Acad Sci USA 2006;103:13180-5.
41. Willis BC, Liebler JM, Luby-Phelps K et al. Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary Ebrosis. Am J Pathol 2005;166: 1321-32.
42. Zeisberg EM, Tarnavski O, Zeisberg M et al. Endothelialto- mesenchymal transition contributes to cardiac fibrosis. Nat Med 2007;13:952-61.
43. Hashimoto N, Phan SH, Imaizumi K et al. Endothelial-mesenchymal transition in bleomycininduced pulmonary fibrosis. Am J Respir Cell Mol Biol 2010;43:161-72.
44. Nataraj D, Ernst A, Kalluri R. Idiopathic pulmonary fibrosis is associated with endothelial to mesenchymal transition. Am J Respir Cell Mol Biol 2010;43:129-30.
45. Ferrara N. The role of VEGF in the regulation of physiological and pathological angiogenesis. In: Clauss M, Breier G, eds. Mechanisms of angiogenesis. Basel, Switzerland: Birkhauser, 2005:209-31.
46. Jinnin M, Makino T, Kajihara I et al. Serum levels of soluble vascular endothelial growth factor receptor-2 in patients with systemic sclerosis. Br J Dermatol 2010;162:751-8.
47. Distler O, Distler JH, Scheid A et al. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res 2004;95:109-16.
48. Hinz B, Phan SH, Thannickal VJ et al. The myofibroblast: one function, multiple origins. Am J Pathol 2007;170: 1807-16.
49. Huang X, Yang N, Fiore VF et al. Matrix stiffness-induced myofibroblast differentiation is mediated by intrinsic mechanotransduction. Am J Respir Cell Mol Biol 2012;47: 340-8.